---
figid: PMC9626029__10-1055-a-1896-7092-i220111-4
pmcid: PMC9626029
image_filename: 10-1055-a-1896-7092-i220111-4.jpg
figure_link: /pmc/articles/PMC9626029/figure/FI220111-4/
number: Fig. 4
figure_title: ''
caption: 'Recommended pathway to evaluate bleeding phenotypes in Waldenström macroglobulinemia,
  with treatment options. Blue: asymptomatic WM; red: symptomatic WM; green: therapy
  recommendations  (Castillo et al 2019). ADAM10, a disintegrin and metalloproteinase
  10; Ag, antigen; aPTT, activated partial thromboplastin time; BM, bone marrow; CBA,
  collagen binding assay; DOAC, direct oral anticoagulant; FBC, full blood count;
  FVIII, factor VIII; IgM, immunoglobulin M; LTA, light transmission aggregometry;
  PFA, platelet function analyzer; PT, prothrombin time; RBC, red blood cell; R:Co:
  ristocetin cofactor assay; ROTEM, rotational thromboelastometry; SE, side effect;
  sGPVI, soluble glycoprotein VI; TEG, thromboelastography; TKI, tyrosine kinase inhibitor;
  VWD, von Willebrand disease; VWF, von Willebrand factor.'
article_title: 'Bleeding Propensity in Waldenström Macroglobulinemia: Potential Causes
  and Evaluation.'
citation: Simone A. Brysland, et al. Thromb Haemost. 2022 Nov;122(11):1843-1857.
year: '2022'

doi: 10.1055/a-1896-7092
journal_title: Thrombosis and Haemostasis
journal_nlm_ta: Thromb Haemost
publisher_name: Georg Thieme Verlag KG

keywords:
- platelet
- Waldenström macroglobulinemia
- receptor
- bleeding

---
